Aethlon Medical Reports Q2 Cost Reduction and Ongoing Cancer Trial Progress

Reuters

2025/11/13

Aethlon Medical Reports <a href="https://laohu8.com/S/QTWO">Q2</a> Cost Reduction and Ongoing Cancer Trial Progress

Aethlon Medical Inc. reported financial results for its fiscal second quarter ended September 30, 2025. The company announced a 48% reduction in operating expenses, reflecting ongoing cost management efforts. As of September 30, 2025, Aethlon held a cash balance of approximately $5.8 million. The company confirmed it has resolved Nasdaq compliance matters and remains listed on the Capital Market. Operationally, recruitment is underway for Cohort 2 of the Australian oncology trial under an amended protocol. Aethlon also continues its collaboration with UCSF on Long COVID research, with a manuscript in preparation for a peer-reviewed journal. Additionally, the company initiated evaluation of its Hemopurifier device compatibility with a simplified blood treatment system.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA22014) on November 12, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2583583813"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583583813\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583583813?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 05:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583583813","market":"us","top_or_hot":-1,"title":"Aethlon Medical Reports Q2 Cost Reduction and Ongoing Cancer Trial Progress","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aethlon Medical Reports <a href=\"https://laohu8.com/S/QTWO\">Q2</a> Cost Reduction and Ongoing Cancer Trial Progress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AEMD\">Aethlon Medical Inc</a>. reported financial results for its fiscal second quarter ended September 30, 2025. The company announced a 48% reduction in operating expenses, reflecting ongoing cost management efforts. As of September 30, 2025, Aethlon held a cash balance of approximately $5.8 million. The company confirmed it has resolved Nasdaq compliance matters and remains listed on the Capital Market. Operationally, recruitment is underway for Cohort 2 of the Australian oncology trial under an amended protocol. Aethlon also continues its collaboration with UCSF on Long COVID research, with a manuscript in preparation for a peer-reviewed journal. Additionally, the company initiated evaluation of its Hemopurifier device compatibility with a simplified blood treatment system.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA22014) on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aethlon Medical Reports Q2 Cost Reduction and Ongoing Cancer Trial Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAethlon Medical Reports Q2 Cost Reduction and Ongoing Cancer Trial Progress\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-13 05:16</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aethlon Medical Reports <a href=\"https://laohu8.com/S/QTWO\">Q2</a> Cost Reduction and Ongoing Cancer Trial Progress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AEMD\">Aethlon Medical Inc</a>. reported financial results for its fiscal second quarter ended September 30, 2025. The company announced a 48% reduction in operating expenses, reflecting ongoing cost management efforts. As of September 30, 2025, Aethlon held a cash balance of approximately $5.8 million. The company confirmed it has resolved Nasdaq compliance matters and remains listed on the Capital Market. Operationally, recruitment is underway for Cohort 2 of the Australian oncology trial under an amended protocol. Aethlon also continues its collaboration with UCSF on Long COVID research, with a manuscript in preparation for a peer-reviewed journal. Additionally, the company initiated evaluation of its Hemopurifier device compatibility with a simplified blood treatment system.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA22014) on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美國抗疫概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDLbhZgRc:1","article_id":"2583583813","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583583813","pubTimestamp":1762982197,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aethlon Medical Inc. reported financial results for its fiscal second quarter ended September 30, 2025. The company announced a 48% reduction in operating expenses, reflecting ongoing cost management efforts. As of September 30, 2025, Aethlon held a cash balance of approximately $5.8 million. The company confirmed it has resolved Nasdaq compliance matters and remains listed on the Capital Market. Operationally, recruitment is underway for Cohort 2 of the Australian oncology trial under an amended protocol. Aethlon also continues its collaboration with UCSF on Long COVID research, with a manuscript in preparation for a peer-reviewed journal. Additionally, the company initiated evaluation of its Hemopurifier device compatibility with a simplified blood treatment system.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpos","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","BK4082":"医疗保健设备","BK4583":"猴痘概念","AEMD":"Aethlon Medical Inc"},"translate_title":"Aethlon Medical报告第二季度成本降低和正在进行的癌症试验进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AEMD":0.9},"content_text":"Aethlon Medical Reports Q2 Cost Reduction and Ongoing Cancer Trial Progress\n    \n\nAethlon Medical Inc. reported financial results for its fiscal second quarter ended September 30, 2025. The company announced a 48% reduction in operating expenses, reflecting ongoing cost management efforts. As of September 30, 2025, Aethlon held a cash balance of approximately $5.8 million. The company confirmed it has resolved Nasdaq compliance matters and remains listed on the Capital Market. Operationally, recruitment is underway for Cohort 2 of the Australian oncology trial under an amended protocol. Aethlon also continues its collaboration with UCSF on Long COVID research, with a manuscript in preparation for a peer-reviewed journal. Additionally, the company initiated evaluation of its Hemopurifier device compatibility with a simplified blood treatment system.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA22014) on November 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}